Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6099018 | 0.88 | NPC1 (0.45) | MAPTCRBNNPC1MAPK13MAPK12 | |
| SCHEMBL15828532 | 0.76 | — | — | |
| SCHEMBL31619130 | 0.75 | AHR (0.42) | MAPTCRBNNPC1MAPK13MAPK12 | |
| SCHEMBL706419 | 0.68 | — | — | |
| SCHEMBL15829265 | 0.68 | MAPT (0.48) | MAPTCRBNNPC1MAPK13MAPK12 | |
| SCHEMBL8620213 | 0.67 | ANPEP (0.32) | — | |
| SCHEMBL8623203 | 0.67 | ALDH1A1 (0.32) | MAPTCRBNTSHRALDH1A1 | |
| SCHEMBL6321531 | 0.67 | FKBP5 (0.34) | MAPTCRBN | |
| SCHEMBL689700 | 0.67 | MAP2K1 (0.46) | MEN1KMT2APARP1MAPK1IDO1 | |
| SCHEMBL15829266 | 0.67 | CRBN (0.44) | MAPTCRBNNPC1MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150592-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150592-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2014094357-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-5789587-A | Heterocyclic-fused lactams promote release of growth hormone | MERCK & CO., INC. (US) | 1998-08-04 | — | — | US | disclosed |
| US-5606054-A | Heterocyclic-fused lactams promote release of growth hormone | MERCK & CO., INC. (US) | 1997-02-25 | — | — | US | disclosed |
| WO-1995016692-A1 | HETEROCYCLIC-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1995-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | NR5A2, NR5A1, GPER1 | MAPT 4520/4885CRBN 1919/4885NPC1 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.